Introduction Kerendia is the brand name for finerenone, a non-steroidal selective mineralocorticoid receptor antagonist (MRA) used to reduce the risk of chronic kidney disease (CKD) progression and cardiovascular complications in adults with chronic kidney disease associated with type 2 diabetes mellitus. Unlike older steroidal MRAs such as spironolactone and eplerenone, finerenone has a unique non-steroidal … Read more
Introduction Empagliflozin is an oral sodium–glucose co-transporter 2 (SGLT2) inhibitor that lowers blood glucose by promoting urinary glucose excretion. It also provides cardiovascular and renal protective benefits, and is approved for type 2 diabetes mellitus, heart failure, and chronic kidney disease. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral, taken once daily Bioavailability ~78% … Read more
Introduction Dapagliflozin is an oral sodium–glucose co-transporter 2 (SGLT2) inhibitor, used to treat type 2 diabetes mellitus (T2DM). Additionally, it offers benefits in heart failure and chronic kidney disease, independent of its glucose-lowering effects. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral, once daily Bioavailability ~78% Protein Binding ~91% Metabolism Glucuronidation (UGT1A9) Half-life … Read more
